Keyphrases
Chemotherapy-induced Peripheral Neuropathy
100%
Neuroprotection
100%
Triamcinolone Acetonide
100%
Peripheral Neuropathy
87%
Cargo
25%
Paclitaxel
25%
Signaling Mechanism
25%
Axonal Degeneration
25%
Mitochondrial Trafficking
25%
Imaging Methods
12%
Co-treatment
12%
Intervention Approaches
12%
Treatment Conditions
12%
Impact-based
12%
Patient Well-being
12%
Therapeutic Candidates
12%
Pharmacological Therapy
12%
Axon
12%
Therapeutic Approaches
12%
Cancer Chemotherapy
12%
Lysosome
12%
Reduction Method
12%
Anterograde
12%
FDA-approved Drugs
12%
Mitochondria
12%
Pharmacological Intervention
12%
Biogenesis
12%
Organelle Trafficking
12%
Clinical Problems
12%
Cancer Chemotherapy Drugs
12%
Golgi
12%
Subcellular Organelles
12%
Neuroprotection Effect
12%
Dosage Reduction
12%
Neuroprotective
12%
Treatment Delay
12%
Drug Screening
12%
Pain Sensation
12%
Neuroprotective Mechanisms
12%
Reticulum
12%
Chemotherapy Side Effects
12%
Anterograde Trafficking
12%
Retrograde Trafficking
12%
Pharmacology, Toxicology and Pharmaceutical Science
Fluocinolone Acetonide
100%
Chemotherapy-Induced Peripheral Neuropathy
100%
Neuroprotection
100%
Neuropathy
87%
Side Effect
50%
Neuroprotective Agent
25%
Paclitaxel
25%
Nerve Fiber Degeneration
25%
Malignant Neoplasm
12%
Cancer Chemotherapy
12%
Drug Screening
12%
Neuroscience
Neuroprotection
100%
Neuropathy
100%
Fluocinolone Acetonide
72%
Signaling Mechanism
18%
Mitochondrion
18%
Paclitaxel
18%
Neuroprotective Agent
18%
Axonal Degeneration
18%
Nerve Fiber Degeneration
18%
In Vitro
9%
Nociception
9%
Lysosome
9%
In Vivo
9%
Axon
9%